Clinical Application of Liquid Biopsy for Precise Diagnosis and Prognosis in Lymphoma

NCT04062877 | Completed

• 1 other identifier: ZDYYGZ201907
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Lymphoma is a highly heterogeneous blood malignancy. It is very important to search for relative specific diagnostic markers that can detect related lymphoma in early stage for the treatment and long-term prognosis of the disease, as the hematopoietic diseases, such as lymphoma, are more difficult to biopsy than solid tumors, with more damage and side effects.Liquid Biopsy (Liquid Biopsy) refers to the extraction of solid biological tissue, is the most common blood, also including saliva, urine, cerebrospinal fluid and other body fluids, and extract the circulating tumor cells (circulating tumor cell, CTC) and circulating tumor DNA (circulating tumor DNA, ctDNA) is used to assess related diseases. CTCs/CSCs have the ability to generate new tumors and play a key role in tumor metastasis.This project intends to develop liquid biopsy technology for accurate diagnosis and prognosis judgment of lymphoma, to carry out clinical transformation application and serve patients.

Conditions

Lymphoma

Keywords

Fluid biopsy; lymphoma; accurate diagnosis

Outcome Measures

Primary Outcomes (2)

• complete remission

  Patients achieve complete remission after initial treatment

  From date of randomization or initial treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 weeks

• relapse

  Patients' disease progress after complete remission

  From date of randomization or complete remission until the date of first documented relapse from any cause，assessed up to 100weeks.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

patients of lymphoma diagnosed of de novo, CR, relapsed/refractory, be willing to receive treatment, aged between 14 to 75 years.

You may qualify if:

• patients of lymphoma diagnosed of de novo, CR, relapsed/refractory, be willing to receive treatment

You may not qualify if:

• leukemia

Sponsors & Collaborators

• Ge Zheng: lead

Study Sites (1)

Institute of Hematology Southeast University Department of Hematology Zhongda Hospital Southeast University Medical School

Nanjing, Jiangsu, 210000, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

patients'samples from peripheral blood

MeSH Terms

Conditions

Lymphoma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Zheng Ge

  Director of Department of Hematology Zhongda Hospital

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Director of Department of Hematology

Study Record Dates

• First Submitted: August 5, 2019
• First Posted: August 20, 2019
• Study Start: July 1, 2018
• Primary Completion: December 30, 2021
• Study Completion: December 30, 2021
• Last Updated: March 24, 2022

Record last verified: 2022-03

Locations

CN (1)